Prothena | PRTA - Interest Expense On Debt


Prothena reported $352.63M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.39B 85.53M Sep/2025
ALKERMES USD 4.65M 1.35M Dec/2024
Alnylam Pharmaceuticals USD 44.4M 4.15M Sep/2025
Amgen USD 685M 9M Sep/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 2.58M 100K Sep/2025
Exelixis USD 23.4M 3.9M Sep/2023
Incyte USD 592K 2K Sep/2025
Ionis Pharmaceuticals USD 18M 1000K Sep/2025
MacroGenics USD 3.34M 2.54M Sep/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Prothena USD 352.63M 46.44M Sep/2025
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Ultragenyx Pharmaceutical USD 14.15M 108K Sep/2025
Vertex Pharmaceuticals USD 3.3M 400K Sep/2025